---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010589"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:59:44.981962+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics reports FY2022 net loss of $12.2M; positive ALS data for COYA 302

## Summary
- Net loss of $12.2M for FY2022 vs $4.9M in FY2021; R&D expense rose to $4.4M from $2.5M.
- Cash and cash equivalents $5.9M at Dec 31, 2022; IPO net proceeds of $14.5M received in Jan 2023.
- Positive proof-of-concept data for COYA 302 in ALS: halted disease progression over 6 months in 4 patients.
- Entered worldwide agreement with Dr. Reddy's to in-license abatacept biosimilar and out-license COYA 301.
- Anticipates IND filing for COYA 301 in FTD and COYA 302 in neurodegenerative diseases in H2 2023.

## SEC filing metadata
- accession: 0000950170-23-010589
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000095017023010589/0000950170-23-010589-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000095017023010589/coya-20230329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010589
- JSON: https://secwatch.observer/filing/0000950170-23-010589.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010589.txt

## Key facts
- Earnings Releases
  Coya Therapeutics, Inc. reported fiscal year ended December 31, 2022 results: net income $12.2 million.
  - Period: fiscal year ended December 31, 2022
  - Net income: $12.2 million
  - Result: reported results
  source text: On March 29, 2023, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000095017023010589/0000950170-23-010589-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.